Saudi has made headlines with a groundbreaking medical achievement at King Abdulaziz Medical City in Riyadh

The medical team has successfully used Casgevy gene therapy to treat a young patient with thalassemia major, marking a significant milestone in the field of gene therapy.

On August 21, 2024, a 13-year-old patient suffering from Mediterranean anemia underwent a transformative procedure using CRISPR gene editing technology

This success story is remarkable because it is the first time this treatment has been applied outside of clinical trials and research. Previously, the patient needed blood transfusions every three weeks to manage his condition, but after receiving the gene therapy, he left the medical city with a full recovery.

This achievement is a game-changer for Saudi Arabia’s medical sector and showcases the country’s growing prowess in advanced gene therapies

Recommended

Saudi Hospital Makes History With World’s First Fully Robotic Heart TransplantSaudi Focuses On Climate Solutions While Joining Arab Nations For Arab Meteorological DaySaudi Health Ministry Urges Residents To Get Flu Vaccine

The Kingdom is now preparing to expand the use of these cutting-edge treatments to patients with sickle cell anemia and other forms of thalassemia. This move is set to strengthen Saudi Arabia’s position in the global gene therapy landscape.

As Saudi continues to embrace innovative medical technologies, this breakthrough represents not only a major step forward in treating genetic disorders but also a beacon of hope for future patients. The successful application of Casgevy gene therapy demonstrates the Kingdom’s commitment to advancing healthcare and improving lives through cutting-edge science.